LifeSci Capital analyst Rami Katkhuda initiated coverage of Mineralys Therapeutics with an Outperform rating and $33 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS:
- Mineralys Therapeutics files to sell 8.89M shares of common stock for holders
- Mineralys Therapeutics files $500M mixed securities shelf
- Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Mineralys Therapeutics reports Q4 EPS (61c), consensus (82c)
- Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024
